- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02296346
Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis (MSECP)
A Randomized, Controlled, Open-Label Study to Evaluate the Efficacy of Extracorporeal Photopheresis (ECP) Versus Corticosteroids in the Treatment of Patients With Secondary Progressive Multiple Sclerosis (SPMS)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a Phase II randomized, open-label study to evaluate the efficacy of extracorporeal photopheresis (ECP) versus IVMP on disability progression in subjects with SPMS. At the initial screening visit, an extensive medical history will be obtained and a detailed neurological examination will be performed to determine eligibility. Subjects who meet eligibility criteria will be enrolled in one of two study arms. Subjects will be randomized at a 1:1 ratio to receive ECP (study arm) or active treatment with intravenous methylprednisolone pulses (control arm) administered every 4 Weeks (1 gram per infusion) for 52 weeks.
ECP will be administered according to the following schedule:
Study Arm: Weeks 1-8: 3 times per week Weeks 9-16: Twice per week Weeks 17-36: Treatment on two consecutive days every 2 weeks (or optionally, one treatment per week) Weeks 37-43: Once every 2 weeks Weeks 44-52: Once every 4 Weeks
All subjects, including patients who receive corticosteroids, will be evaluated using the MSFC tool at baseline and every 3 months through 2 years. They will also be scored using the EDSS at baseline and every 3 months through 2 years. Subjects in the control arm will be evaluated by MSFC and EDSS during the week prior to their next intravenous methylprednisolone infusion and every three months from baseline through two year mark. Blood will be collected for immune function (cytokines) testing at baseline, and months 3, 6, 9 and 12. MRI will be done at baseline as well as months 6 and 12 following initiation of treatment; if the disability measurements are stable or improved at any point in time, then ECP will be continued per protocol..
Patients in the ECP arm should have all of their treatments with the CELLEX ® System. Patients randomized to the ECP arm must receive their treatment within 5 days of baseline visit.
In the ECP process, UVADEX ® (methoxsalen) Sterile Solution will be injected directly the recirculation bag of the extracorporeal circuit after completion of the buffy coat collection. The dose of UVADEX® (methoxsalen) Sterile Solution will be calculated based on the standard treatment volume formula.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan Health Systems
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with SPMS based on the Recommended Diagnostic Criteria for MS and clinical course.
- Demonstrate EDSS scores between 3 to 6.5 at screening.
- Documented EDSS progression in the 2 years prior to screening of 1 point or greater for patients with an EDSS score less than 6 at baseline, and greater than or equal to 0.5
- Documented absence of clinical relapse within 2 years of screening
- Age ≥ 18 ≤ 75 years
- Weight > 40≤ 150 kg.
- Absolute Neutrophil count ≥ 2,000 per μL
- Hematocrit ≥ 28 % and platelet count > 100,000 per μL (with or without transfusion support)
- Willingness to use at least 1 reliable method of birth control (e.g. abstinence, oral contraceptives, intrauterine devices, barrier method with spermicide, or surgical sterilization) throughout the study for all men and women of childbearing potential
- Willingness to participate in all study visits and procedures, as outlined in the informed consent
- Patients able to give informed consent.
- Patients must have adequate peripheral venous access to initiate ECP therapy.
Exclusion Criteria:
- Absolute medical contraindication to corticosteroid treatment
- Absolute medical contraindication to receive ECP
- Clinical relapse within 2 years of screening
Laboratory evidence of any of the following:
- WBC < 2,000 cells per uL
- Serum transaminase levels > x 2 UNL
- HgbA1C > 6%
- Concurrent diagnosis of a neurological condition or autoimmune disease other than MS
- Evidence of known infection with human immunodeficiency virus (HIV) or active (not including latent) Hepatitis B (laboratory testing is not required if virus status is already known)
- Uncontrolled infection requiring treatment at study entry
- Hypersensitivity or allergy to psoralen (methoxsalen)
- Hypersensitivity or allergy to both heparin and citrate products (If hypersensitive or allergic to only one of these products, exclusion does not apply)
- Inability to tolerate fluid changes associated with ECP (e.g. inadequate renal, hepatic, pulmonary and cardiac function leading to enable patient to tolerate extracorporeal volume shifts associated with ECP)
- Presence of aphakia or photosensitive disease (systemic lupus erythematosis, porphyrias, albinism, etc.)
- Women who are pregnant and/or lactating.
- Use of any investigational drug/treatment at the time of enrollment or within the previous 60 days, or five elimination half-lives, or until the expected pharmacodynamic effect has returned to baseline, whichever is longer.
- Initiation of dalfampridine or change in the dose of dalfampridine within 6 months prior to randomization
Treatment with any of the medications or procedures listed below:
- Glatiramer acetate, interferon-beta, fingolimod, teriflunomide or dimethylfumarate within 3 months prior to randomization
- Natalizumab within 6 months prior to randomization
- Cyclophosphamide within 1year prior to randomization
- Mitoxantrone within 2 years prior to randomization
- Rituximab, ofatumumab, ocrelizumab, cladribine, daclizumab within 2 years prior
- Intravenous immunoglobulin within 6 months prior to randomization
- Plasmapheresis within 1 year prior to randomization
- Corticosteroids within 3 months prior to screening
- Inability to undergo MRI scans
- Contraindication to gadolinium due to past allergic, hypersensitive or adverse reaction or impaired renal function
- Any other disease or condition which, in the opinion of the investigator, could interfere with participation in the study according to the study protocol, or with the ability of the patients to cooperate and comply with study procedures.
- Poor venous access
- Previous history of skin cancer, leukemia/lymphoma/myeloma or bone marrow transplant.
- History of cataracts
- Patients taking Coumadin who are unable to switch from oral anticoagulants to enoxaparin.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Corticosteroid arm
Patients will receive 1 gram of IV SoluMedrol over 1 hour, once every month for 12 months.
|
Infusion of drug subcutaneously, once a month.
Other Names:
|
Experimental: Extracorporeal Photopheresis
Patient will receive an Extracorporeal Photopheresis treatment at a set frequency over the course of 1 year. The treatment takes about 2-3 hours per session to complete. The treatment schedule is as follows: ECP will be administered according to the following schedule: Study Arm: Weeks 1-8: 3 times per week Weeks 9-16: Twice per week Weeks 17-36: Treatment on two consecutive days every 2 weeks (or optionally, one treatment per week) Weeks 37-43: Once every 2 weeks Weeks 44-52: Once every 4 Weeks |
This intervention is the placement of up to two IV's to extract your blood as a set volume, separate out the white cells and return the red cells to your body.
Then the white cells are treated with a drug called UVADEX (methoxsalen), excited by a UV light and returned to your body.
Once IV is to withdraw your blood and the other is to return your blood to your body.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Multiple Sclerosis Functional Composite (MSFC) Z-score and Expanded Disability Status Scale (EDSS)
Time Frame: 1 year
|
MSFC score is a composite score calculated from 3 tests: 1) Timed 25-Foot walk (leg function); 2) 9-Hole Peg Test (arm function); and 3) Paced Auditory Serial Addition Test (cognitive function). The results are combined to create a single score (the MSFC Z-Score) to measure performance and change over time in subjects with MS. MSFC Z-score = {Z arm + Z leg + Z cognitive} / 3.0. A positive score indicates that, on average, an individual performed better than the reference population and a negative score indicates that, on average, an individual performed worse than the reference population. The Expanded Disability Status Scale (EDSS) is used to quantify disability due to symptoms of MS and to track changes in disability status over time. Scores range from 0 (normal neurological exam) to 10 (death due to multiple sclerosis). Scores are determined by performing a neurological exam and given in increments of 0.5. |
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunological Parameters in Relation to SPMS
Time Frame: 2 year
|
Changes in immunological parameters that occur following initiation of ECP or corticosteroids and any relevant correlation with clinical outcomes
|
2 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Benjamin Segal, MD, University of Michigan, Director of Multiple Sclerosis Center
- Principal Investigator: Daniel Couriel, MD, University of Utah, Huntsman Cancer Institute, Internal Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Neoplasms
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Neoplastic Processes
- Multiple Sclerosis
- Multiple Sclerosis, Chronic Progressive
- Sclerosis
- Neoplasm Metastasis
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Neuroprotective Agents
- Protective Agents
- Prednisolone
- Methylprednisolone Acetate
- Methylprednisolone
- Methylprednisolone Hemisuccinate
- Prednisolone acetate
- Prednisolone hemisuccinate
- Prednisolone phosphate
Other Study ID Numbers
- HUM00083301
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Secondary Progressive Multiple Sclerosis
-
Casa Sollievo della Sofferenza IRCCSNeurocenter of Southern Switzerland; Associazione Revert ONLUS; Fondazione Cellule...CompletedSecondary-progressive Multiple SclerosisItaly, Switzerland
-
Tiziana Life Sciences LTDWithdrawnMultiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis
-
BioMS Technology Corp.TerminatedMultiple Sclerosis, Secondary Progressive
-
University College, LondonLondon School of Hygiene and Tropical Medicine; The Leeds Teaching Hospitals... and other collaboratorsActive, not recruitingSecondary Progressive Multiple Sclerosis (SPMS)United Kingdom
-
State University of New York at BuffaloCompletedSecondary-progressive Multiple SclerosisUnited States
-
Novartis PharmaceuticalsActive, not recruitingRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
University of MinnesotaMallinckrodtTerminatedPrimary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
University of UtahCompletedMultiple Sclerosis | Multiple Sclerosis, Secondary Progressive | Secondary Progressive Multiple SclerosisUnited States
-
Tehran University of Medical SciencesCompletedMultiple Sclerosis | Mesenchymal Stem Cells | Secondary-Progressive Multiple SclerosisIran, Islamic Republic of
-
Novartis PharmaceuticalsActive, not recruitingActive Secondary Progressive Multiple SclerosisItaly
Clinical Trials on SoluMedrol
-
Dawn BrewerNational Institute of Environmental Health Sciences (NIEHS)Completed
-
Elza AbdessaterCompleted
-
CMH RWP Combined Military Hospital RWP: RawalpindiCompletedSensorineural Hearing Loss | TinnitusPakistan
-
University of ManitobaCompletedOdontogenic Infection of Jaw (Disorder)Canada
-
Jean Charles DoucetNova Scotia Health AuthorityCompletedProspective Evaluation of Perioperative Steroid Dosing on Postsurgical Edema in Orthognathic SurgeryPost-operative Edema | Steroid UseCanada
-
Minneapolis Heart Institute FoundationAbbott Medical DevicesCompleted
-
Nayera Hazaa ElsherifCompletedIdiopathic Thrombocytopenic PurpuraEgypt
-
Universidade Federal do Rio de JaneiroRio de Janeiro State Research Supporting Foundation (FAPERJ); Instituto de... and other collaboratorsWithdrawnAcute Respiratory Distress Syndrome | Acute Lung InjuryBrazil
-
University of Southern CaliforniaCompleted
-
National Liver Institute, EgyptQuesna Central Hospital, Ministry Of Health, EgyptCompleted